STAAR Surgical Company
HealthcareNASDAQ:STAA · NASDAQ Global Market
-$0.53 today
Vol 0.38M · Avg 1.13M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-23.4%
avg -3.5%
ROIC
-11.3%
avg -1.8%
ROA
-17.4%
avg -1.8%
Analysis
ROIC is currently the strongest return metric at -11.3% versus its period average of -1.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Warren Foust | Interim Co-CEO, President & COO | $1.44M | — | 49 | $32,990.00 | 0.07% |
Deborah J. Andrews | Interim Co-CEO & CFO | $1.18M | — | 69 | $15,699.00 | 0.03% |
Magda Michna | Chief Development Officer | $895,716.00 | — | — | $43,688.00 | 0.09% |
Scott D. Barnes | Chief Medical Officer | $691,149.00 | — | 63 | $41,502.00 | 0.08% |
Kathleen Determann | VP, Deputy General Counsel and Chief Compliance & Privacy Officer | — | — | — | — | — |
Connie Johnson | Director of Investor Relations | — | — | — | — | — |
Filip De Keersmaecker | Senior Vice President of Global E2E Supply Chain | — | — | — | — | — |
Nancy Sabin | Chief Marketing Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
22
$62.75M
Sells
0
$0.00
Net Sentiment
+$62.75M
Net buying
Most Active
BROADWOOD PARTNERS, L.P.
22 transactions
1–10 of 22
Analysis
Insiders reported 22 buys worth $62.75M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $62.75M. BROADWOOD PARTNERS, L.P. was the most active insider with 22 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | +6.5% | +12.8% (16yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +6.5% over three years. Forward estimates point to Revenue at +12.8% (16yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Terns Pharmaceuticals, Inc.
TERN
$4.77B
NovoCure Limited
NASDAQ:NVCR
$2.06B
Pulse Biosciences, Inc.
NASDAQ:PLSE
$1.69B
Precigen, Inc.
NASDAQ:PGEN
$1.34B
BioLife Solutions, Inc.
NASDAQ:BLFS
$1.28B
Tourmaline Bio, Inc.
TRML
$1.23B
Kestra Medical Technologies, Ltd.
NASDAQ:KMTS
$1.22B
Azenta, Inc.
NASDAQ:AZTA
$1.04B
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
$856.09M
Beta Bionics, Inc.
NASDAQ:BBNX
$647.48M
Who manages STAA?
STAAR Surgical Company (STAA) lists 8 active executives. The top listed executive is Scott D. Barnes, Chief Medical Officer.
Are STAA insiders buying or selling?
Recent insider activity shows net buying of $106.76M.
Explore More
Continue the stock analysis
Jump to another research area for this company.